“Risk factors for severe hypoglycemia included younger and older age, prior severe hypoglycemia, use of insulin, sulfonylurea, two-drug therapy including sulfonylurea or glinides, three-or-more-drug therapy, excessive polypharmacy, and comorbidities including end-stage renal disease (ESRD) requiring dialysis.”
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
About aging: trials about aging, of every trial that tests the drug for any use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
1 lab
18 trials, 1 about aging, 5 with no results posted
Funders: Teijin Pharma and 1 more
1 of 1 finding with company ties
Human trial1
Humans12
What is Sulfonylurea linked with?
1
Studies link Sulfonylurea with 1 measure, most often severe hypoglycemia (1 study).
Severe hypoglycemia
↑upin humans1
1 study
Sulfonylurea raises the risk of severe hypoglycemia in humans.
“Risk factors for severe hypoglycemia included younger and older age, prior severe hypoglycemia, use of insulin, sulfonylurea, two-drug therapy including sulfonylurea or glinides, three-or-more-drug therapy, excessive polypharmacy, and comorbidities including end-stage renal disease (ESRD) requiring dialysis.”
Humansin patients with type 2 diabetes using glucose-lowering drugsn = 93,801
In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.
Crude rates of hospitalization or death were 18.6 per 100 person-years with GLP-1 drugs against 16.7 with other diabetes drugs, with an adjusted hazard ratio of 1.05.Crude rates of hospitalization or death were 18.6 per 100 person-years with GLP-1 drugs against 16.7 with other diabetes drugs, with an adjusted hazard ratio of 1.05.
Median age at diagnosis rose from 63.0 years in 2005–2008 to 66.7 years in 2020–2023, alongside more coexisting illnesses and lower blood sugar.Median age at diagnosis rose from 63.0 years in 2005–2008 to 66.7 years in 2020–2023, alongside more coexisting illnesses and lower blood sugar.